Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Cancer drugs are the primary concern in terms of drug development trends.

The global Cancer Biopharmaceuticals market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Cancer Biopharmaceuticals in Liquid Cancers is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Cancer Biopharmaceuticals include Sanofi, Johnson & Johnson, Pfizer, Novartis, Merck, GlaxoSmithKline, Eli Lilly, Agios Pharmaceuticals and Bristol-Myers Squibb, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cancer Biopharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Biopharmaceuticals.

Report Scope

The Cancer Biopharmaceuticals market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Biopharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cancer Biopharmaceuticals companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cancer Biopharmaceuticals Market Report

Report Metric	Details
Report Name	Cancer Biopharmaceuticals Market
Segment by Type	Biologics Biosimilars
Segment by Application	Liquid Cancers Solid Cancers
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sanofi, Johnson & Johnson, Pfizer, Novartis, Merck, GlaxoSmithKline, Eli Lilly, Agios Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Biopharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cancer Biopharmaceuticals Market report?

Ans: The main players in the Cancer Biopharmaceuticals Market are Sanofi, Johnson & Johnson, Pfizer, Novartis, Merck, GlaxoSmithKline, Eli Lilly, Agios Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics

What are the Application segmentation covered in the Cancer Biopharmaceuticals Market report?

Ans: The Applications covered in the Cancer Biopharmaceuticals Market report are Liquid Cancers, Solid Cancers

What are the Type segmentation covered in the Cancer Biopharmaceuticals Market report?

Ans: The Types covered in the Cancer Biopharmaceuticals Market report are Biologics, Biosimilars

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Biologics

1.2.3 Biosimilars

1.3 Market by Application

1.3.1 Global Cancer Biopharmaceuticals Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Liquid Cancers

1.3.3 Solid Cancers

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cancer Biopharmaceuticals Market Perspective (2019-2030)

2.2 Cancer Biopharmaceuticals Growth Trends by Region

2.2.1 Global Cancer Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Cancer Biopharmaceuticals Historic Market Size by Region (2019-2024)

2.2.3 Cancer Biopharmaceuticals Forecasted Market Size by Region (2025-2030)

2.3 Cancer Biopharmaceuticals Market Dynamics

2.3.1 Cancer Biopharmaceuticals Industry Trends

2.3.2 Cancer Biopharmaceuticals Market Drivers

2.3.3 Cancer Biopharmaceuticals Market Challenges

2.3.4 Cancer Biopharmaceuticals Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cancer Biopharmaceuticals Players by Revenue

3.1.1 Global Top Cancer Biopharmaceuticals Players by Revenue (2019-2024)

3.1.2 Global Cancer Biopharmaceuticals Revenue Market Share by Players (2019-2024)

3.2 Global Cancer Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Cancer Biopharmaceuticals Revenue

3.4 Global Cancer Biopharmaceuticals Market Concentration Ratio

3.4.1 Global Cancer Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cancer Biopharmaceuticals Revenue in 2023

3.5 Cancer Biopharmaceuticals Key Players Head office and Area Served

3.6 Key Players Cancer Biopharmaceuticals Product Solution and Service

3.7 Date of Enter into Cancer Biopharmaceuticals Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Cancer Biopharmaceuticals Breakdown Data by Type

4.1 Global Cancer Biopharmaceuticals Historic Market Size by Type (2019-2024)

4.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2025-2030)

5 Cancer Biopharmaceuticals Breakdown Data by Application

5.1 Global Cancer Biopharmaceuticals Historic Market Size by Application (2019-2024)

5.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Cancer Biopharmaceuticals Market Size (2019-2030)

6.2 North America Cancer Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Cancer Biopharmaceuticals Market Size by Country (2019-2024)

6.4 North America Cancer Biopharmaceuticals Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cancer Biopharmaceuticals Market Size (2019-2030)

7.2 Europe Cancer Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Cancer Biopharmaceuticals Market Size by Country (2019-2024)

7.4 Europe Cancer Biopharmaceuticals Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Cancer Biopharmaceuticals Market Size (2019-2030)

8.2 Asia-Pacific Cancer Biopharmaceuticals Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2019-2024)

8.4 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Cancer Biopharmaceuticals Market Size (2019-2030)

9.2 Latin America Cancer Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Cancer Biopharmaceuticals Market Size by Country (2019-2024)

9.4 Latin America Cancer Biopharmaceuticals Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cancer Biopharmaceuticals Market Size (2019-2030)

10.2 Middle East & Africa Cancer Biopharmaceuticals Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2019-2024)

10.4 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sanofi

11.1.1 Sanofi Company Detail

11.1.2 Sanofi Business Overview

11.1.3 Sanofi Cancer Biopharmaceuticals Introduction

11.1.4 Sanofi Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.1.5 Sanofi Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Detail

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Cancer Biopharmaceuticals Introduction

11.2.4 Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.2.5 Johnson & Johnson Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Detail

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Cancer Biopharmaceuticals Introduction

11.3.4 Pfizer Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.3.5 Pfizer Recent Development

11.4 Novartis

11.4.1 Novartis Company Detail

11.4.2 Novartis Business Overview

11.4.3 Novartis Cancer Biopharmaceuticals Introduction

11.4.4 Novartis Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.4.5 Novartis Recent Development

11.5 Merck

11.5.1 Merck Company Detail

11.5.2 Merck Business Overview

11.5.3 Merck Cancer Biopharmaceuticals Introduction

11.5.4 Merck Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.5.5 Merck Recent Development

11.6 GlaxoSmithKline

11.6.1 GlaxoSmithKline Company Detail

11.6.2 GlaxoSmithKline Business Overview

11.6.3 GlaxoSmithKline Cancer Biopharmaceuticals Introduction

11.6.4 GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.6.5 GlaxoSmithKline Recent Development

11.7 Eli Lilly

11.7.1 Eli Lilly Company Detail

11.7.2 Eli Lilly Business Overview

11.7.3 Eli Lilly Cancer Biopharmaceuticals Introduction

11.7.4 Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.7.5 Eli Lilly Recent Development

11.8 Agios Pharmaceuticals

11.8.1 Agios Pharmaceuticals Company Detail

11.8.2 Agios Pharmaceuticals Business Overview

11.8.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Introduction

11.8.4 Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.8.5 Agios Pharmaceuticals Recent Development

11.9 Bristol-Myers Squibb

11.9.1 Bristol-Myers Squibb Company Detail

11.9.2 Bristol-Myers Squibb Business Overview

11.9.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Introduction

11.9.4 Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.9.5 Bristol-Myers Squibb Recent Development

11.10 AstraZeneca

11.10.1 AstraZeneca Company Detail

11.10.2 AstraZeneca Business Overview

11.10.3 AstraZeneca Cancer Biopharmaceuticals Introduction

11.10.4 AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.10.5 AstraZeneca Recent Development

11.11 Mylan

11.11.1 Mylan Company Detail

11.11.2 Mylan Business Overview

11.11.3 Mylan Cancer Biopharmaceuticals Introduction

11.11.4 Mylan Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.11.5 Mylan Recent Development

11.12 LEO Pharma

11.12.1 LEO Pharma Company Detail

11.12.2 LEO Pharma Business Overview

11.12.3 LEO Pharma Cancer Biopharmaceuticals Introduction

11.12.4 LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.12.5 LEO Pharma Recent Development

11.13 Boehringer Ingelheim

11.13.1 Boehringer Ingelheim Company Detail

11.13.2 Boehringer Ingelheim Business Overview

11.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Introduction

11.13.4 Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.13.5 Boehringer Ingelheim Recent Development

11.14 Alexion Pharmaceuticals

11.14.1 Alexion Pharmaceuticals Company Detail

11.14.2 Alexion Pharmaceuticals Business Overview

11.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Introduction

11.14.4 Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.14.5 Alexion Pharmaceuticals Recent Development

11.15 Elusys Therapeutics

11.15.1 Elusys Therapeutics Company Detail

11.15.2 Elusys Therapeutics Business Overview

11.15.3 Elusys Therapeutics Cancer Biopharmaceuticals Introduction

11.15.4 Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2019-2024)

11.15.5 Elusys Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Agios Pharmaceuticals

Alexion Pharmaceuticals

Elusys Therapeutics

List of Tables

Table 1. Global Cancer Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Biologics

Table 3. Key Players of Biosimilars

Table 4. Global Cancer Biopharmaceuticals Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Cancer Biopharmaceuticals Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Cancer Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Cancer Biopharmaceuticals Market Share by Region (2019-2024)

Table 8. Global Cancer Biopharmaceuticals Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Cancer Biopharmaceuticals Market Share by Region (2025-2030)

Table 10. Cancer Biopharmaceuticals Market Trends

Table 11. Cancer Biopharmaceuticals Market Drivers

Table 12. Cancer Biopharmaceuticals Market Challenges

Table 13. Cancer Biopharmaceuticals Market Restraints

Table 14. Global Cancer Biopharmaceuticals Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Cancer Biopharmaceuticals Market Share by Players (2019-2024)

Table 16. Global Top Cancer Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biopharmaceuticals as of 2023)

Table 17. Ranking of Global Top Cancer Biopharmaceuticals Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Cancer Biopharmaceuticals Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Cancer Biopharmaceuticals Product Solution and Service

Table 21. Date of Enter into Cancer Biopharmaceuticals Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Cancer Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2019-2024)

Table 25. Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2025-2030)

Table 27. Global Cancer Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2019-2024)

Table 29. Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2025-2030)

Table 31. North America Cancer Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Cancer Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Cancer Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Cancer Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Cancer Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Cancer Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Cancer Biopharmaceuticals Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Cancer Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Cancer Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Cancer Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Cancer Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 46. Sanofi Company Detail

Table 47. Sanofi Business Overview

Table 48. Sanofi Cancer Biopharmaceuticals Product

Table 49. Sanofi Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 50. Sanofi Recent Development

Table 51. Johnson & Johnson Company Detail

Table 52. Johnson & Johnson Business Overview

Table 53. Johnson & Johnson Cancer Biopharmaceuticals Product

Table 54. Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 55. Johnson & Johnson Recent Development

Table 56. Pfizer Company Detail

Table 57. Pfizer Business Overview

Table 58. Pfizer Cancer Biopharmaceuticals Product

Table 59. Pfizer Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 60. Pfizer Recent Development

Table 61. Novartis Company Detail

Table 62. Novartis Business Overview

Table 63. Novartis Cancer Biopharmaceuticals Product

Table 64. Novartis Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 65. Novartis Recent Development

Table 66. Merck Company Detail

Table 67. Merck Business Overview

Table 68. Merck Cancer Biopharmaceuticals Product

Table 69. Merck Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 70. Merck Recent Development

Table 71. GlaxoSmithKline Company Detail

Table 72. GlaxoSmithKline Business Overview

Table 73. GlaxoSmithKline Cancer Biopharmaceuticals Product

Table 74. GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 75. GlaxoSmithKline Recent Development

Table 76. Eli Lilly Company Detail

Table 77. Eli Lilly Business Overview

Table 78. Eli Lilly Cancer Biopharmaceuticals Product

Table 79. Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 80. Eli Lilly Recent Development

Table 81. Agios Pharmaceuticals Company Detail

Table 82. Agios Pharmaceuticals Business Overview

Table 83. Agios Pharmaceuticals Cancer Biopharmaceuticals Product

Table 84. Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 85. Agios Pharmaceuticals Recent Development

Table 86. Bristol-Myers Squibb Company Detail

Table 87. Bristol-Myers Squibb Business Overview

Table 88. Bristol-Myers Squibb Cancer Biopharmaceuticals Product

Table 89. Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 90. Bristol-Myers Squibb Recent Development

Table 91. AstraZeneca Company Detail

Table 92. AstraZeneca Business Overview

Table 93. AstraZeneca Cancer Biopharmaceuticals Product

Table 94. AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 95. AstraZeneca Recent Development

Table 96. Mylan Company Detail

Table 97. Mylan Business Overview

Table 98. Mylan Cancer Biopharmaceuticals Product

Table 99. Mylan Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 100. Mylan Recent Development

Table 101. LEO Pharma Company Detail

Table 102. LEO Pharma Business Overview

Table 103. LEO Pharma Cancer Biopharmaceuticals Product

Table 104. LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 105. LEO Pharma Recent Development

Table 106. Boehringer Ingelheim Company Detail

Table 107. Boehringer Ingelheim Business Overview

Table 108. Boehringer Ingelheim Cancer Biopharmaceuticals Product

Table 109. Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 110. Boehringer Ingelheim Recent Development

Table 111. Alexion Pharmaceuticals Company Detail

Table 112. Alexion Pharmaceuticals Business Overview

Table 113. Alexion Pharmaceuticals Cancer Biopharmaceuticals Product

Table 114. Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 115. Alexion Pharmaceuticals Recent Development

Table 116. Elusys Therapeutics Company Detail

Table 117. Elusys Therapeutics Business Overview

Table 118. Elusys Therapeutics Cancer Biopharmaceuticals Product

Table 119. Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 120. Elusys Therapeutics Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Cancer Biopharmaceuticals Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Cancer Biopharmaceuticals Market Share by Type: 2023 VS 2030

Figure 3. Biologics Features

Figure 4. Biosimilars Features

Figure 5. Global Cancer Biopharmaceuticals Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Cancer Biopharmaceuticals Market Share by Application: 2023 VS 2030

Figure 7. Liquid Cancers Case Studies

Figure 8. Solid Cancers Case Studies

Figure 9. Cancer Biopharmaceuticals Report Years Considered

Figure 10. Global Cancer Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 11. Global Cancer Biopharmaceuticals Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Cancer Biopharmaceuticals Market Share by Region: 2023 VS 2030

Figure 13. Global Cancer Biopharmaceuticals Market Share by Players in 2023

Figure 14. Global Top Cancer Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biopharmaceuticals as of 2023)

Figure 15. The Top 10 and 5 Players Market Share by Cancer Biopharmaceuticals Revenue in 2023

Figure 16. North America Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 17. North America Cancer Biopharmaceuticals Market Share by Country (2019-2030)

Figure 18. United States Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. Canada Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Europe Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Cancer Biopharmaceuticals Market Share by Country (2019-2030)

Figure 22. Germany Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. France Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. U.K. Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Italy Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Russia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Nordic Countries Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Asia-Pacific Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Cancer Biopharmaceuticals Market Share by Region (2019-2030)

Figure 30. China Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Japan Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. South Korea Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Southeast Asia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. India Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Australia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Latin America Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Cancer Biopharmaceuticals Market Share by Country (2019-2030)

Figure 38. Mexico Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Brazil Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Middle East & Africa Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Cancer Biopharmaceuticals Market Share by Country (2019-2030)

Figure 42. Turkey Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Saudi Arabia Cancer Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Sanofi Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 45. Johnson & Johnson Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 46. Pfizer Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 47. Novartis Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 48. Merck Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 49. GlaxoSmithKline Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 50. Eli Lilly Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 51. Agios Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 53. AstraZeneca Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 54. Mylan Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 55. LEO Pharma Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 56. Boehringer Ingelheim Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 57. Alexion Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 58. Elusys Therapeutics Revenue Growth Rate in Cancer Biopharmaceuticals Business (2019-2024)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-36S14110

Thu May 02 00:00:00 UTC 2024

Add to Cart

High Capacity Endotoxin Removal Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-14G14630

Thu May 02 00:00:00 UTC 2024

Add to Cart

Rapid Endotoxin Removal Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-7R14828

Thu May 02 00:00:00 UTC 2024

Add to Cart

Automated Complete Blood Cell Counter - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-38S14317

Thu May 02 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Cancer Biopharmaceuticals Market Research Report 2024

Published Date: March 2024

Report Code: QYRE-Auto-25N5869

Global Cancer Biopharmaceuticals Market Research Report 2024

FEATURED COMPANIES

Cancer Biopharmaceuticals Market

Report Scope

Scope of Cancer Biopharmaceuticals Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Cancer Biopharmaceuticals Market report?

What are the Application segmentation covered in the Cancer Biopharmaceuticals Market report?

What are the Type segmentation covered in the Cancer Biopharmaceuticals Market report?

FEATURED COMPANIES

RELATED REPORTS